- Home
- AHG vs IVA Comparison
AHG vs IVA Comparison
Compare AHG & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AHG
- IVA
- Stock Information
- Founded
- AHG 2013
- IVA 2011
- Country
- AHG China
- IVA France
- Employees
- AHG N/A
- IVA N/A
- Industry
- AHG Business Services
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- AHG Consumer Discretionary
- IVA Health Care
- Exchange
- AHG Nasdaq
- IVA Nasdaq
- Market Cap
- AHG 939.1M
- IVA 769.0M
- IPO Year
- AHG N/A
- IVA 2020
- Fundamental
- Price
- AHG $1.83
- IVA $5.46
- Analyst Decision
- AHG
- IVA Strong Buy
- Analyst Count
- AHG 0
- IVA 6
- Target Price
- AHG N/A
- IVA $15.33
- AVG Volume (30 Days)
- AHG 9.1K
- IVA 71.5K
- Earning Date
- AHG 09-12-2025
- IVA 09-26-2025
- Dividend Yield
- AHG N/A
- IVA N/A
- EPS Growth
- AHG N/A
- IVA N/A
- EPS
- AHG N/A
- IVA N/A
- Revenue
- AHG $14,777,798.00
- IVA $14,591,573.00
- Revenue This Year
- AHG N/A
- IVA $80.35
- Revenue Next Year
- AHG N/A
- IVA N/A
- P/E Ratio
- AHG N/A
- IVA N/A
- Revenue Growth
- AHG 512.09
- IVA N/A
- 52 Week Low
- AHG $0.74
- IVA $1.53
- 52 Week High
- AHG $2.35
- IVA $6.50
- Technical
- Relative Strength Index (RSI)
- AHG 55.43
- IVA 58.24
- Support Level
- AHG $1.65
- IVA $5.21
- Resistance Level
- AHG $1.95
- IVA $5.78
- Average True Range (ATR)
- AHG 0.11
- IVA 0.35
- MACD
- AHG 0.00
- IVA -0.03
- Stochastic Oscillator
- AHG 65.71
- IVA 47.09
About AHG Akso Health Group ADS
Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.